Janumet

Metformin hydrochloride and sitagliptin, the active ingredient in Janumet, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels when diet and exercise alone are insufficient.

GNH USA supplies Janumet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across global markets.

Janumet is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder that impairs glucose regulation. - Type 2 diabetes mellitus: improves glycemic control in adults when diet, exercise, and monotherapy are insufficient. - Inadequate control on metformin alone: adds additional glucose‑lowering effect through DPP‑4 inhibition. - Combination therapy with diet and exercise: assists patients in achieving target blood glucose and HbA1c levels.

Janumet may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild to moderate. - Upper respiratory tract infection: common cold‑like symptoms. - Hypoglycemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or liver injury. - Severe hypoglycemia: profound low blood glucose requiring assistance. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating Janumet, clinicians should consider several safety factors. - Renal function monitoring: assess creatinine clearance to avoid accumulation. - Hepatic function assessment: evaluate liver enzymes for potential dysfunction. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. - Elderly patients: start at lower dose and monitor closely for adverse effects. - Hypersensitivity: discontinue if allergic reactions occur. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Janumet can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycemia. - Iodinated contrast agents: may precipitate lactic acidosis in renal impairment. - Alcohol excess: heightens lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: combined effect on renal function. - Beta‑blockers: can mask hypoglycemia symptoms. - Oral contraceptives: may slightly alter glucose metabolism.